Federal Pharmacy Forum: Atrial Fibrillation: What's New and What Should We Do?

Description

Atrial fibrillation is the most common arrhythmia treated in the United States. It affects millions of Americans annually with estimates that the prevalence will surpass 12 million by 2030. The complications of atrial fibrillation, including hemodynamic compromise, stroke, and heart failure, greatly affect quality of life and increase morality. With its high prevalence, especially in the aging population, appropriate treatment is critical. Pharmacists play a vital role in the management of this disease state. In 2019, the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society published an update to the 2014 Guideline for the Management of Atrial Fibrillation. Attendees of this session will be familiarized with the updates from this guideline including the role of non-vitamin K oral anticoagulants and aspirin. In addition, controversial areas of practice including the use of triple therapy in atrial fibrillation patients undergoing coronary stent placement and anticoagulation in patients with valvular atrial fibrillation will be discussed. The session will use a case-based approach to determine the most appropriate treatments based on patient specific factors.

Pharmacist Learning Objectives

At the completion of this activity, participants will be able to: 

  1. Discuss the 2019 AHA/ACC/HRS Focused Update of the 2014 Guideline for Management of Patients with Atrial Fibrillation recommendations.
  2. Given a patient case, assess the need for anticoagulation and choose an appropriate regimen.
  3. Discuss the role of triple therapy in atrial fibrillation patients undergoing coronary stent placement.

 

Technician Learning Objectives

At the completion of this activity, participants will be able to: 

  1. Identify medications used for stroke prevention in atrial fibrillation patients.
  2. Identify appropriate doses of anticoagulants used for stroke prevention in atrial fibrillation.
  3. List the components of triple therapy used in atrial fibrillation patients undergoing coronary stent placement.

 

 
 
 
Speakers:
Kathleen
Kathleen Lusk, Pharm.D., BCPS
Associate Professor
University of the Incarnate Word Feik School of Pharmacy
 
Interest: Federal
Learning Level: Level 2
Pathway: Pharmacy Technician
Track: Federal Pharmacy Forum
Session Time Slot(s): 
Date: 
Friday, March 20
Time: 
10:15 AM - 11:15 AM
Room: 
Gaylord National Resort - Riverview Ballroom
ACPE Pharmacist: 0202-0000-20-101-L01-P
CEUs Pharmacist: 0.1
ACPE Pharmacy Technician: 0202-0000-20-101-L01-T
CEUs Pharmacy Technician: 0.1
Activity Type:
Application-based